Thiogenesis Therapeutics (TSXV:TTI) Inventories, Raw Materials & Components: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:TTI Thiogenesis Therapeutics Corp TSXV:TTI
24 GF Score
Price C$0.54
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Inventories, Raw Materials & Components?

Thiogenesis Therapeutics TSXV:TTI 24 Inventories, Raw Materials & Components is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSXV:TTI with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Thiogenesis Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was C$0.00 Mil.

Thiogenesis Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics Inventories, Raw Materials & Components Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:TTI
24GF Score
Thiogenesis Therapeutics Corp TSXV:TTI
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of C$0.00 Mil mean?
Thiogenesis Therapeutics (TSXV:TTI) has a Inventories, Raw Materials & Components of C$0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Thiogenesis Therapeutics and its competitors.
Is Thiogenesis Therapeutics' Inventories, Raw Materials & Components too high?
Thiogenesis Therapeutics' current Inventories, Raw Materials & Components is C$0.00 Mil. Overall, Thiogenesis Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Inventories, Raw Materials & Components compare to VRTX and REGN?
Thiogenesis Therapeutics' Inventories, Raw Materials & Components of C$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current Inventories, Raw Materials & Components is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TSXV:TTI) has a current Inventories, Raw Materials & Components of C$0.00 Mil. The current Inventories, Raw Materials & Components is C$0.00 Mil. Thiogenesis Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Thiogenesis Therapeutics (TSXV:TTI), the current Inventories, Raw Materials & Components is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges TTIPF:USAQ8M:Germany
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
24GF Score

Get the complete analysis for TSXV:TTI

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.54
Price